Beigene Ltd 6160-HK:Hong Kong Stock Exchange

*Data is delayed | Exchange | HKD
Last | 4:08 PM CTT
101.80quote price arrow down-1.20 (-1.17%)
Volume
1,410,736
52 week range
82.65 - 167.30
Loading...
  • Open102.40
  • Day High103.60
  • Day Low100.80
  • Prev Close103.00
  • 52 Week High167.30
  • 52 Week High Date04/14/23
  • 52 Week Low82.65
  • 52 Week Low Date02/14/24

Key Stats

  • Market Cap16,876M
  • Shares Out1,359.51M
  • 10 Day Average Volume1.86M
  • Dividend-
  • Dividend Yield-
  • Beta0.65
  • YTD % Change-7.54

KEY STATS

  • Open102.40
  • Day High103.60
  • Day Low100.80
  • Prev Close103.00
  • 52 Week High167.30
  • 52 Week High Date04/14/23
  • 52 Week Low82.65
  • 52 Week Low Date02/14/24
  • Market Cap16,876M
  • Shares Out1,359.51M
  • 10 Day Average Volume1.86M
  • Dividend-
  • Dividend Yield-
  • Beta0.65
  • YTD % Change-7.54

RATIOS/PROFITABILITY

  • EPS (TTM)-5.08
  • P/E (TTM)-20.03
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beigene Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small...
John Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Xiaobin Wu
President, Chief Operating Officer, General Manager - China
Julia Wang
Chief Financial Officer
Address
94 Solaris Avenue,, Camana Bay
Grand Cayman, BEJ
KY1-1108
Cayman Islands